We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LEO Pharma Announces Agreement with Ubiquigent To Access Novel Compounds
Product News

LEO Pharma Announces Agreement with Ubiquigent To Access Novel Compounds

LEO Pharma Announces Agreement with Ubiquigent To Access Novel Compounds
Product News

LEO Pharma Announces Agreement with Ubiquigent To Access Novel Compounds


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "LEO Pharma Announces Agreement with Ubiquigent To Access Novel Compounds"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ubiquigent and LEO Pharma have announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.

Ubiquigent and LEO Pharma also entered into an agreement in 2018, as part of LEO Pharma Open Innovation, with the objective of evaluating a collection of Ubiquigent’s novel compounds across LEO Pharma’s in-house disease-relevant assays. This approach identified a number of active compounds, two of which will now be subject to the agreement announced today.

Ubiquigent’s Managing Director, Mr. Jason Mundin commented, "LEO Pharma Open Innovation has been an excellent way to test hypotheses and uncover new opportunities. We are pleased to be entering into this latest agreement and look forward to following the development of the compounds with our colleagues at LEO Pharma."

Vice President of Global Research at LEO Pharma, Thorsten Thormann commented, "We are very excited to announce this collaboration with Ubiquigent. Through this new kind of partnership LEO Pharma is strengthening our research capabilities and disease understanding, extending our reach as the world expert in medical dermatology".

Ubiquigent is a company that enables and supports protein degradation focused drug discovery via modulation and exploitation of the ubiquitin system. Its approach includes the capability to design and develop early-stage novel compounds both as part of its Collaborative Drug Discovery partnerships but also on its own account for subsequent partnering. LEO Pharma specializes in medical dermatology providing critical care products for the treatment of a number of indications including psoriasis, atopic dermatitis and eczema.

LEO Pharma Open Innovation invites anyone in the field of science to have their molecules tested using LEO Pharma research resources. Head of Open Innovation Niclas Nilsson said, "The unique setup of LEO Pharma Open Innovation creates the ideal circumstance for us to uncover what we didn’t know about, allowing for the exploration of completely novel targets and opportunities, which we probably wouldn’t be able to identify otherwise."

Advertisement